Name: ACRV Income Statement - Acrivon Therapeutics Revenue & EPS | Ledgeburg
Creator: Ledgeburg
License: https://creativecommons.org/licenses/by/4.0/
Keywords: Revenue, Cost of Revenue, Gross Profit, Operating Expenses, Operating Income, Net Income, EPS Basic, EPS Diluted

JavaScript is disabled. Some features may not work properly. For the best experience, please enable JavaScript in your browser.

ACRV - Acrivon Therapeutics, Inc.

USD | NASDAQ | Healthcare

ACRV Income Statement - Acrivon Therapeutics Revenue & EPS | Ledgeburg

(in millions of USD, except per-share data)	Q1 FY 26	Q4 FY 25	Q3 FY 25	Q2 FY 25	Q1 FY 25	Q4 FY 24	Q3 FY 24	Q2 FY 24	Q1 FY 24	Q4 FY 23	Q3 FY 23	Q2 FY 23	Q1 FY 23	Q4 FY 22	Q3 FY 22	Q2 FY 22	Q1 FY 22	Q4 FY 21	Q3 FY 21	Q2 FY 21	Q1 FY 21
Revenues
Revenues	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Source: SEC EDGAR company filings. Figures as reported (US GAAP)

(in millions of USD, except per-share data)	TTM	FY2025	FY2024	FY2023	FY2022	FY2021
Revenues
Revenues	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Expenses
Research & Development	59.7	60.0	64.0	46.0	23.9	-
Selling General & Administrative	-	-	-	-	-	-
Operating Income
Operating Income	(82.4)	(84.1)	(89.2)	(67.1)	(32.7)	(16.2)
Non-Operating
Interest Income	-	-	-	7.0	1.5	-
Interest Expense	-	-	-	-	-	-
Income From Equity Investments
Tax & Net
Income Tax Expense	-	0.0	-	-	-	-
Net Income From Continuing Ops	(77.3)	(77.9)	(80.6)	(60.4)	(31.2)	(16.2)
Net Income From Discontinued Ops
Per Share
EPS Basic	(2.00)	(2.02)	(2.38)	(2.74)	(7.56)	(9.32)
EPS Diluted	(2.00)	(2.02)	(2.38)	(2.74)	(7.56)	(9.32)
Shares Basic
Supplementary Data
EBITDA	(80.9)	(82.8)	(88.2)	(66.6)	(32.3)	(16.1)
EBIT	(82.4)	(84.1)	(89.2)	(67.1)	(32.7)	(16.2)

Source: SEC EDGAR company filings. Figures as reported (US GAAP)

Operating Expenses
Research & Development	15.2	14.7	13.6	16.2	15.4	18.6	18.9	15.0	11.5	15.5	10.3	10.5	9.8	-	-	-	-	-	-	-	-
Selling General & Administrative	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Selling & Marketing	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General & Administrative	4.7	5.4	6.0	6.5	6.2	6.3	6.3	6.4	6.2	5.6	5.9	5.0	4.6	-	-	-	-
Depreciation & Amortization	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.2	0.2	0.2	0.1	0.1	0.1	0.1	0.1	0.1
Amortization of Intangibles	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Operating Expenses	19.9	20.1	19.7	22.6	21.7	25.0	25.1	21.4	17.7	21.1	16.1	15.5	14.4	9.9	9.6	5.9

Operating Income
Operating Income	(19.9)	(20.1)	(19.7)	(22.6)	(21.7)	(25.0)	(25.1)	(21.4)	(17.7)	(21.1)	(16.1)	(15.5)	(14.4)	(9.9)	(9.6)	(5.9)	(7.2)	-	(2.7)	-	-

Non-Operating
Interest Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income From Equity Investments	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Non-Operating Income	0.9	1.1	1.5	1.6	2.0	2.1	2.7	2.6	1.2	1.8	1.7	1.6	1.6	1.0	0.4	0.1	(0.0)
Pre-Tax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Tax & Net
Income Tax Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income From Continuing Ops	(19.0)	(19.0)	(18.2)	(21.0)	(19.7)	(22.8)	(22.4)	(18.8)	(16.5)	(19.3)	(14.5)	(13.9)	(12.8)	(8.9)	(9.2)	(5.8)	(7.2)
Net Income From Discontinued Ops	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	(19.0)	(19.0)	(18.2)	(21.0)	(19.7)	(22.8)	(22.4)	(18.8)	(16.5)	(19.3)	(14.5)	(13.9)	(12.8)	(8.9)	(9.2)	(5.8)	(7.2)
Net Income Attributable To Parent	(19.0)	(19.0)	(18.2)	(21.0)	(19.7)	(22.8)	(22.4)	(18.8)	(16.5)	(19.3)	(14.5)	(13.9)	(12.8)	(8.9)	(9.2)	(5.8)
Less: Minority Interest	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Less: Preferred Dividends	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income To Common Shareholders	(19.0)	(19.0)	(18.2)	(21.0)	(19.7)	(22.8)	(22.4)	(18.8)	(16.5)	(19.3)	(14.5)	(13.9)	(12.8)	(8.9)	(9.2)

Per Share
EPS Basic	(0.49)	-	(0.47)	(0.55)	(0.51)	-	(0.59)	(0.52)	(0.73)	-	(0.66)	(0.63)	(0.58)	-	(5.17)	(3.29)	(4.08)	-	(1.38)	-	-
EPS Diluted	(0.49)	-	(0.47)	(0.55)	(0.51)	-	(0.59)	(0.52)	(0.73)	-	(0.66)	(0.63)	(0.58)	-	(5.17)	(3.29)	(4.08)	-
Shares Basic	38.7	-	38.6	38.5	38.4	-	38.1	36.1	22.6	-	22.1	22.0	21.9	-	1.8	1.8	1.8	-
Shares Diluted	38.7	-	38.6	38.5	38.4	-	38.1	36.1	22.6	-	22.1	22.0	21.9	-	1.8	1.8	1.8	-

Supplementary Data
EBITDA	(19.5)	(19.7)	(19.4)	(22.3)	(21.4)	(24.7)	(24.8)	(21.2)	(17.4)	(20.8)	(16.0)	(15.4)	(14.3)	(9.8)	(9.5)	(5.8)	(7.2)	-	(2.7)	-	-
EBIT	(19.9)	(20.1)	(19.7)	(22.6)	(21.7)	(25.0)	(25.1)	(21.4)	(17.7)	(21.1)	(16.1)	(15.5)	(14.4)	(9.9)	(9.6)	(5.9)	(7.2)	-	(2.7)